Caption Management’s Allogene Therapeutics ALLO Stock Holding History

Caption Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-153,400	Closed	-$758K	–	1074
2023 Q1	$758K	Buy	153,400 +123,400	+411%	+$791K	0.01%	693
2022 Q4	$189K	Buy	+30,000	New	+$278K	﹤0.01%	1072
2021 Q3	–	Sell	-30,000	Closed	-$782K	–	1475
2021 Q2	$782K	Hold	30,000	–	–	0.01%	955
2021 Q1	$1.06M	Buy	+30,000	New	+$1.01M	0.02%	670
2020 Q3	–	Sell	-40,000	Closed	-$1.71M	–	1008
2020 Q2	$1.71M	Buy	40,000 +12,500	+45%	+$452K	0.06%	415
2020 Q1	$535K	Sell	27,500 -2,500	-8%	-$59.5K	0.03%	530
2019 Q4	$780K	Buy	30,000 +16,500	+122%	+$454K	0.03%	550
2019 Q3	$369K	Buy	+13,500	New	+$384K	0.02%	523

Other funds holding ALLO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caption Management's ALLO Position: Q2 2025 in Review

Caption Management sold out of Allogene Therapeutics (ALLO) in Q2 2025, closing a stake of 15,000 shares — an estimated $21.9K sold.

Caption Management first reported a position in ALLO in Q4 2019 and held it in 8 quarters. The position peaked at $480K in Q4 2019. 158 funds tracked by Wall St. Rank hold ALLO as of Q2 2025.

Caption Management reported no remaining Allogene Therapeutics position as of Q2 2025 after selling out during the quarter.
Caption Management sold 15,000 Allogene Therapeutics shares in Q2 2025, an estimated $21.9K.
Caption Management first reported a position in Allogene Therapeutics in Q4 2019 and held it in 8 quarters.
Caption Management's Allogene Therapeutics position peaked at $480K in Q4 2019.
158 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.